VIR•benzinga•
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
Summary
Vir Biotechnology's Phase 2 study on hepatitis B treatments shows promising antigen loss rates, with up to 46% achieving seroclearance in key regimens.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 15, 2024 by benzinga